aparat aparat telegram1  ar en fa

ساعت کار مرکـز :

شنبه تا 4شنبه: ساعت 8 الی 22 - 5شنبه ها: ساعت 8 الی 14

instagram takipçi satın al indoXploit shell PUBG Lite

پیش بینی عود سرطان پستان

جدیدترین روش در پیش بینی عود سرطان پستان :

Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.
King TA, et al. J Clin Oncol. 2016.
Show full citation

PURPOSE: The objective of this study was to determine whether the 21-gene Recurrence Score (RS) provides clinically meaningful information in patients with de novo stage IV breast cancer enrolled in the Translational Breast Cancer Research Consortium (TBCRC) 013.

PATIENTS AND METHODS: TBCRC 013 was a multicenter prospective registry that evaluated the role of surgery of the primary tumor in patients with de novo stage IV breast cancer. From July 2009 to April 2012, 127 patients from 14 sites were enrolled; 109 (86%) patients had pretreatment primary tumor samples suitable for 21-gene RS analysis. Clinical variables, time to first progression (TTP), and 2-year overall survival (OS) were correlated with the 21-gene RS by using log-rank, Kaplan-Meier, and Cox regression.

RESULTS: Median patient age was 52 years (21 to 79 years); the majority had hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative (72 [66%]) or hormone receptor-positive/HER2-positive (20 [18%]) breast cancer. At a median follow-up of 29 months, median TTP was 20 months (95% CI, 16 to 26 months), and median survival was 49 months (95% CI, 40 months to not reached). An RS was generated for 101 (93%) primary tumor samples: 22 (23%) low risk (< 18), 29 (28%) intermediate risk (18 to 30); and 50 (49%) high risk (≥ 31). For all patients, RS was associated with TTP (P = .01) and 2-year OS (P = .04). In multivariable Cox regression models among 69 patients with estrogen receptor (ER)-positive/HER2-negative cancer, RS was independently prognostic for TTP (hazard ratio, 1.40; 95% CI, 1.05 to 1.86; P = .02) and 2-year OS (hazard ratio, 1.83; 95% CI, 1.14 to 2.95; P = .013).

CONCLUSION: The 21-gene RS is independently prognostic for both TTP and 2-year OS in ER-positive/HER2-negative de novo stage IV breast cancer. Prospective validation is needed to determine the potential role for this assay in the clinical management of this patient subset.

© 2016 by American Society of Clinical Oncology.
PMID 27001590 [PubMed - as supplied by publisher]
Full text
Full text at journal site
Citation 15 of 10088
Back to results Next
Similar articles

Clinical outcome in women with HER2-positive de novo or recurring stage IV breast cancer receiving trastuzumab-based therapy.
Rossi V, et al. Breast. 2014.
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Martin M, et al. Breast Cancer Res. 2014.
Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J, et al. Breast Cancer. 2015.
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial.
Randomized controlled trial
Linardou H, et al. Breast Cancer Res. 2012.
Overview of resistance to systemic therapy in patients with breast cancer.
Review article
Gonzalez-Angulo AM, et al. Adv Exp Med Biol. 2007.
See all
Full website NIH NLM NCBI Help

خواندن 1466 دفعه
شنبه, 04 ارديبهشت 1395 15:51 چاپ

نظرات (0)

تاکنون نظری برای این مطلب ارسال نشده است.

نظر خود را اضافه کنید.

در قالب میهمان نظر خود را ارسال کنید. ثبت نام کنید یا وارد شوید به حساب کاربریتان.
0 Characters
پیوست ها (0 / 3)
Share Your Location

اطلاعات مرکز

آدرس: اصفهان - خیابان شمس آبادی-چهارراه قصر-مجتمع قصرنور-طبقه 5-واحد501
تلفن‌های تماس: 32240047-031 - 09130748424
تلفن گویا: 9730361
فکس  : 03132240047
کدپستی: 3165844567
ایمیل: info@novintahlilgaran.com


رفتن به بالا